An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Solid Tumors
DRUG: XmAb24306|DRUG: Atezolizumab|DRUG: XmAb24306
Percentage of Participants with Adverse Events, Up to approximately 4 years
Serum Concentration of XmAb24306, Baseline, then at pre-defined intervals for the first year of treatment or until participant discontinues study treatment|Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Up to approximately 4 years|Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1, Up to approximately 4 years|Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1, Up to approximately 4 years|ORR as Based on Radiographic Assessment by the Investigator Using Modified RECIST v1.1 for Immune-Based Therapeutics (iRECIST), Up to approximately 4 years|DOR as Based on Radiographic Assessment by the Investigator Using iRECIST, Up to approximately 4 years|PFS as Based on Radiographic Assessment by the Investigator Using iRECIST, Up to approximately 4 years|Overall Survival (OS), Up to approximately 4 years
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.